New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
08:44 EDTPTXPernix Therapeutics upgraded at Needham
As previously reported, Needham upgraded Pernix to Strong Buy from Buy. The analyst said Pernix's purchase of Treximet is a "game changer" and should increase short-term profitability and provides an anchor in the CNS market. Price target raised to $10 from $9.
News For PTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 9, 2016
07:29 EDTPTXPernix Therapeutics price target lowered to $8 from $14 at Brean Capital
Brean Capital lowered its price target on Pernix Therapeutics to $8 from $14 to reflect the removal of any growth premium after it was reported that the company will explore strategic alternatives. The firm believes the company's assets are undervalued and the timing of a deal given market volatility is not ideal. Brean Capital maintained its Buy rating on Pernix shares.
February 8, 2016
14:58 EDTPTXPernix Therapeutics exploring strategic alternatives, Reuters says
Subscribe for More Information
14:54 EDTPTXPernix Therapeutics exploring strategic alternatives, Reuters reports
February 2, 2016
09:39 EDTPTXPernix Therapeutics management to meet with Needham
Meeting to be held in New York on February 4 hosted by Needham.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use